CLINICAL_TRIALS
trial_result
· 2020-08-07
Clinical Trial Update: Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer [Phase 2]
Summary
Phase 2 clinical trial evaluating individualized axitinib scheduling for metastatic renal cell cancer has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Case Comprehensive Cancer Center | Conditions: Metastatic Renal Cell Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-08-07